Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CollaGenex Pharmaceuticals
Newtown, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CollaGenex developed Oracea®, the first FDA-approved systemic therapy for rosacea. Clinical trials showed significant reduction in inflammatory lesions compared to placebo. Other pipeline products included incyclinide for acne/rosacea and COL‑118 for erythema of rosacea[6][7]. The company also marketed Periostat® for periodontitis.
- Therapeutic areas
- DermatologyInfectious DiseasesNephrology
- Modalities
- Small moleculeSynthetic glucocorticoid corticosteroid (for Pandel)Combination drug (for Alcortin and Novacort)
- Industry
- Biotech
02
Partnerships
Medigene AG – licensing agreement for Oracea marketing rights in EU/certain countries[5]Primus Pharmaceuticals – promotion/cooperation agreements on Alcortin™ and Novacort™ [5]Altana AG/Taisho Pharmaceutical – licensing agreement on Pandel®
Beyond the preview
Go deeper on CollaGenex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CollaGenex Pharmaceuticals.